For more than 40 years, Genentech has been dedicated to rigorous and groundbreaking science, developing therapies for unmet medical needs. Today, the Genentech Research and Early Development (gRED) organization shapes the future of medicine by discovering and developing life-changing therapies through pioneering science in the areas of oncology, immunology, ophthalmology, neuroscience and infectious disease.
gRED aspires to make fundamental scientific discoveries and to develop these discoveries into first or best-in-class medicines made in the best interest of our patients. To reach these goals, we actively encourage creativity, discussion and leadership among our researchers, welcoming the diverse skills and backgrounds each member brings to the gRED team. gRED is committed to hiring, developing, enabling and leading world-class talent.
Headquartered in South San Francisco, gRED houses the largest single-site biotech research facility in the world and functions as an independent research organization within the Roche Group. The scientists who work here consistently patent and publish important papers in peer-reviewed journals and earn national recognition for their work — nine of our researchers are members of the National Academy of Sciences. Employees often say that gRED combines the best of the corporate and academic worlds, allowing researchers to not only conduct high-quality science with esteemed colleagues, but also to watch an idea move from the laboratory into development and out to a patient in a clinic.